Abhishek A. Mangaonkar

Author

Also Known As

A A Mangaonkar, A. Mangaonkar, Abhishek A Mangaonkar, Abhishek A. Mangaonkar, Abhishek Avinash Mangaonkar, Abhishek Mangaonkar, Abhishek Mangoankar, Abishek A. Mangaonkar, Yelena Ginzburg

379

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic in Arizona Mayo Clinic WinnMed Mayo Clinic in Florida Moffitt Cancer Center

About

Abhishek A. Mangaonkar is an author at Mayo Clinic in Arizona specializing in medicine, pathology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	632
2	Health Sciences	7	7	249
3	Cell Biology	4	4	100
4	Public Health	1	1	33
5	Blood Transplantation	1	1	18

Abhishek A. Mangaonkar

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population Puru Rattan, Daniel D. Penrice, Joseph Ahn, Hepatology Communications	2021	367
Clinical Heterogeneity of the VEXAS Syndrome Matthew J. Koster, Taxiarchis Kourelis, Kaaren K. Reichard, Mayo Clinic Proceedings Down SyndromeRheumatologyVenous DiseaseAutoimmune DiseaseGenetic Disorder	2021	103
Spectrum of clonal hematopoiesis in VEXAS syndrome Fernanda Gutierrez‐Rodrigues, Yael Kusne, Jenna Fernandez, Blood	2023	98
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients Giacomo Coltro, Abhishek A. Mangaonkar, Terra L. Lasho, Leukemia Hematological MalignancyChronic Myelomonocytic LeukemiaMedicineHematologyMyeloid Neoplasia	2019	95
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis Ryan M. Carr, Denis Vorobyev, Terra L. Lasho, Nature Communications	2021	95
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients Tucker Coston, Prateek Pophali, Rangit Vallapureddy, American Journal of Hematology	2019	69
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients Naseema Gangat, Omer Karrar, Moazah Iftikhar, American Journal of Hematology	2023	67
Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia Mrinal M. Patnaik, David A. Sallman, Abhishek A. Mangaonkar, Blood	2020	53
<i>Asxl1</i> loss cooperates with oncogenic <i>Nras</i> in mice to reprogram the immune microenvironment and drive leukemic transformation Xiaona You, Fabao Liu, Moritz Binder, Blood	2021	50
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients Marissa Li, Moritz Binder, Terra L. Lasho, Blood Advances	2021	44

Page 1